stoxline Quote Chart Rank Option Currency Glossary
  
Timber Pharmaceuticals, Inc. (TMBR)
0.3426  0.003 (0.74%)    11-28 15:59
Open: 0.3411
High: 0.35
Volume: 130,464
  
Pre. Close: 0.3401
Low: 0.3202
Market Cap: 1(M)
Technical analysis
2024-02-16 4:25:11 PM
Short term     
Mid term     
Targets 6-month :  0.03 1-year :  0.05
Resists First :  0.03 Second :  0.05
Pivot price 0
Supports First :  0 Second :  0
MAs MA(5) :  0 MA(20) :  0
MA(100) :  1.54 MA(250) :  1.78
MACD MACD :  -0.1 Signal :  -0.2
%K %D K(14,3) :  14.3 D(3) :  23.9
RSI RSI(14): 26.8
52-week High :  3.39 Low :  0
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ TMBR ] has closed above bottom band by 37.5%. Bollinger Bands are 98.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 30 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0 - 0 0 - 0
Low: 0 - 0 0 - 0
Close: 0 - 0 0 - 0
Company Description

Timber Pharmaceuticals LLC, a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-002, a proprietary topical formulation of rapamycin, which is in Phase 2b clinical trial for the treatment of facial angiofibroma in tuberous sclerosis complex, a multisystem genetic disorder resulting in the growth of hamartomas in multiple organs. It is also involved in the development of TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. In addition, the company engages in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. It has license agreement with AFT Pharmaceuticals Limited. The company was founded in 2019 and is headquartered in Basking Ridge, New Jersey.

Headline News

Wed, 29 Nov 2023
Timber Pharmaceuticals Announces Commencement of NYSE American Delisting Proceedings: Common Stock ... - GlobeNewswire

Tue, 28 Nov 2023
Timber Pharmaceuticals Receives Court Approval of All “First Day” Motions to Support Business Operations ... - Yahoo Finance

Fri, 17 Nov 2023
Timber Pharmaceuticals files for Chapter 11 in wake of failed merger (NYSE:TMBR) - Seeking Alpha

Mon, 21 Aug 2023
Timber Pharmaceuticals to be Acquired by LEO Pharma - GlobeNewswire

Mon, 21 Aug 2023
LEO Pharma Signs Agreement to Acquire Timber Pharmaceuticals - Business Wire

Mon, 21 Aug 2023
Why Is Timber Pharmaceuticals (TMBR) Stock Up 96% Today? - InvestorPlace

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
AMEX
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 3 (M)
Shares Float 3 (M)
Held by Insiders 1.1 (%)
Held by Institutions 7.7 (%)
Shares Short 8 (K)
Shares Short P.Month 32 (K)
Stock Financials
EPS -1.98
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.87
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -137.3 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -4.24
Qtrly Earnings Growth 0 %
Operating Cash Flow -14 (M)
Levered Free Cash Flow -6 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value -0.01
Price to Sales 0
Price to Cash Flow -0.01
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android